ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Other Events
Item 8.01. Other Events.
On April5, 2017, the Company issued a press release announcing
that it has entered into the Purchase Agreement for the
registered direct offering of its ADSs.A copy of the press
release is attached hereto as Exhibit99.1 to this Current Report
on Form8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits. The following exhibits are furnished as part of
this Report on Form8-K:
|
ExhibitNo. |
|
DescriptionofExhibit |
|
1.1 |
Purchase Agreement, dated April5, 2017, between Adaptimmune |
|
|
99.1 |
Press Release dated April5, 2017 |
About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region. ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Recent Trading Information
ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) closed its last trading session up +0.02 at 6.09 with 451,557 shares trading hands.